A r t i c l e s 575 cases with cardiovascular defects, 1,776 with epilepsy and/or seizure disorder, 1,379 with autism spectrum disorder and 3,898 with craniofacial defects (Supplementary Tables 1 and 2) .
We analyzed DNA samples obtained from whole blood using customized array comparative genomic hybridization (CGH) at an average probe density of ~97,000 oligonucleotides, which is sufficient for reliable genome-wide detection of CNVs >300 kb and for targeted detection of events >40 kb for approximately one-fourth of the genome 13 . After filtering, a total of 16,526 rare (<1% population frequency) autosomal CNV calls were made with an average of 1.05 CNV events per individual (with a median CNV size of 213 kb). Using a customized higher density microarray and fluorescent in situ hybridization, we validated 402 of 425 CNVs (with a precision of 0.945) greater than 150 kb (Supplementary Note and Supplementary  Table 3 ). Similarly, manual inspection of calls with low log ratios or z-scores (with absolute values of log ratios < 0.25 and z-scores < 1.5) suggests a false discovery rate of 0.0138. For comparison, we identified CNVs from a control set of 8,329 adult samples assayed using multiple Illumina genome-wide SNP microarrays. These samples were studied as part of genome-wide association studies (dbGaP) for phenotypes unrelated to neurological disease (for example, lipid concentration levels, blood pressure, asthma and so on) ( Supplementary Table 4 ). We called CNVs using a Hidden Markov Model (HMM)-based discovery method 14 with an overall precision of 0.892 in identifying large CNVs (>100 kb) (with 6/6 and 19/22 validated calls) 15, 16 . From this dataset, we identified 446,736 CNVs with an average of 53.6 events (rare and common) per individual (and a median size of 1.9 kb). Because of the increased probe density (most controls assayed using arrays with >550,000 probes), our control dataset provides increased CNV detection power and resolution when compared to the disease dataset, reducing the potential for spurious CNV enrichments within cases (see Online Methods).
CNV burden
We compared CNV content between the cases and controls excluding common CNVs (>1% population frequency). Consistent with previous studies of pediatric neurological disease [3] [4] [5] 17, 18 , we found a significant excess of large CNVs among cases relative to controls. This excess is evident at 250-kb CNVs and becomes more pronounced with increasing CNV size (Fig. 1a) . For example, at a threshold of 400 kb, ~25.7% (4,047 cases) of the children we studied with intellectual disability and/or developmental delay harbor an event of at least this size compared to 11.5% of the controls, suggesting that an estimated 14.2% of intellectual disability and/or developmental delay in this cohort is caused by the presence of CNVs >400 kb in length (odds ratio (OR) = 2.7, P = 5.86 × 10 −158 ). At a threshold of 1.5 Mb, we identified 1,782 (11.3%) affected individuals compared to only 52 (0.6%) controls (OR = 20.3, P = 6.87 × 10 −266 ), and at a threshold of 3.0 Mb, this odds ratio jumps to 47.7 (P = 1.68 × 10 −197 ). There is a remarkably strong correlation (r 2 = 0.97) with the de novo rate as a function of increasing CNV size, with 50% of events at 1 Mb reported as inherited ( Supplementary Fig. 1) .
We detected 1,492 CNVs in 1,400 individuals within 45 known genomic disorder regions ( Table 1 and Supplementary Table 5 ). Among these individuals, deletions are twice as common (n = 954 deletions compared to n = 538 duplications) and show greater average penetrance (80.3%) when compared to duplications (71.1% penetrance). We note that 'classic' phenotypically well defined syndromes known to result from CNVs (for example, Smith-Magenis syndrome and Williams syndrome) are underrepresented here relative to other cohorts of individuals with similar phenotypes (Supplementary Table 6 ), suggesting that our estimate of CNV burden in intellectual disability and/or developmental delay is not upwardly biased by ascertainment for known CNV carriers.
Examining the size distribution of CNVs in the context of major subphenotypes shows that the large CNV burden is increased in more severe developmental phenotypes associated with multiple congenital abnormalities. We find, for example, that children also diagnosed with craniofacial and cardiovascular defects showed a significantly increased burden of large CNVs when compared to children with autism spectrum disorder (P = 4.99 × 10 −10 and P = 6.45 × 10 −5 , respectively, at >400 kb) ( Fig. 1b) . Children with an additional diagnosis of epilepsy and/or severe seizure disorder tended to have a more intermediate CNV burden when compared to individuals with autism or more severe intellectual disability ( Supplementary Fig. 2 ). These distinctions remained significant even after excluding CNVs larger than 10 Mb (which would have been detectable by karyotype analysis) and when the CNV burden among the subset of controls screened for psychiatric disease was used as the baseline, showing a role for large CNVs in more severe phenotypic variation. A r t i c l e s Locus-specific enrichments A comparison of the CNV landscape between cases and controls shows striking differences and some general genomic architectural features ( Fig. 2) . To compensate for the effects of breakpoint imprecision and multi-platform comparisons, we contrasted the number of deletions (or duplications) present in cases versus controls in 200-kb windows along the human genome using a Fisher's exact test (Supplementary Table 7 and Supplementary Fig. 3 ). This analysis identified 80 genomic regions that were at least weakly enriched for CNVs (counting deletions and duplications separately) among cases (with at least five windows having P < 0.1), 27 of which showed strong evidence for enrichment (P < 0.001). Notably, 27.5% (22/80) of the enriched CNV loci reside at genomic hotspots flanked by large (>10 kb) blocks of highly similar (>90%) segmental duplication and include most known genomic disorders ( Supplementary Table 7 ). An additional 46 enrichments represent large CNVs near telomeres ( Supplementary Fig. 4 ). Although we observed enrichments at one or both ends of all chromosomes, 12 chromosome ends showed particularly strong (P < 0.001) enrichment. Of the 80 CNV loci, 15 are new or are supported by isolated case reports ( Table 2) . Additional phenotypic details for CNV carriers, including ethnicity and inheritance status, at each of these 15 CNV loci are provided in Supplementary  Table 8 , in some cases with comparison to similar CNVs observed in case reports from DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources) 19 . We note that one of these 15 CNVs (duplications at 10p15.3) appears to be enriched among cases as a consequence of allelic stratification between the African and European populations and was thus eliminated from further consideration (Online Methods and Supplementary Note). Among the 14 newly discovered CNV loci for intellectual disability and/or developmental delay, we identified a 660-kb deletion mapping to chromosome 15q25.2 flanked by segmental duplications (69.8 kb, 98.6% identity) ( Fig. 3a) . The deletion is absent from the controls analyzed here and from the Database of Genomic Variants (see URLs) but is present in five affected individuals (including two siblings) among the intellectual disability and/or developmental delay sample set. Clinical aspects of the probands were variable and consisted of neurologic features and developmental delay ( Supplementary Table 9 ); one female had only mild motor delay associated with a congenital myopathy but was otherwise cognitively normal. The two brothers with the deletion both had autism spectrum disorders, but additional family members were not tested (Supplementary Note). A previous meta-analysis found this deletion in 4 of 6,860 cases 16 with schizophrenia and autism compared to 0 of 5,674 controls (combined with this study, P = 0.037 after excluding one sibling). Thus, although the statistical significance remains modest and population stratification cannot be definitively ruled out (Supplementary Note), these data suggest a potentially new genomic disorder that will be observed at a frequency of 1/3,000 referred cases.
One of the most common genomic hotspots in this study is at 15q11.2 (NIPA1), a 292-kb deletion whose pathogenicity has been considered uncertain 4, 20 . In terms of frequency, the 15q11.2 deletion is second only to the velocardiofacial/DiGeorge syndrome (VCF/DGS) deletion, and our data indicate that it is significantly enriched (OR = 2.59, P = 2.5 × 10 −5 ), albeit at lower penetrance (12.8%) than those in most other genomic disorders. In addition, we find support for the pathogenicity of duplications of obesity-associated 16p11.2 (SH2B1) 21, 22 and epilepsy-associated 15q13.3 (CHRNA7) 23 . We also analyzed 111 regions of the human genome predicted to be prone to recurrent microdeletions and microduplications based on the presence of homologous segmental duplications at their flanks in the reference assembly 6 . Of these potential hotspots, 62 harbored CNVs likely mediated by nonallelic homologous recombination between the flanking segmental duplications ('active hotspots'), whereas the remaining 49 did not. Fig. 5 ). Notably, we identified eight regions that showed no evidence of copy number variation in cases or controls despite the presence of large, highly similar and directly oriented segmental duplications at their flanks ( Supplementary  Table 10 ). These may be regions that are mutationally active but in which dosage imbalance is lethal (for example, 7p14.3, flanked by 19.9-kb duplications and containing BBS9 and BMPER).
In addition to identifying new potentially pathogenic loci, the large number of cases analyzed provided the opportunity to identify atypical deletions (deletions characterized by noncanonical breakpoints and likely not generated by non-allelic homologous recombination mutational mechanism) and refine the critical region of known genomic disorders. For example, we identified three individuals with smaller, atypical deletions within the 17q21.31 microdeletion syndrome region 6, 24, 25 (Fig. 3b) . The breakpoints in these cases contrast with those of 23 cases carrying the canonical 480-kb deletion mediated by unequal crossover between directly orientated segmental duplications-a genomic architecture largely restricted to individuals of European descent 26 . Detailed clinical information on two individuals with the atypical deletion ( Fig. 3c) showed strong phenotypic similarity with the known syndrome, including a pronounced philtrum, epicanthic folds, cupped ears and skeletal defects of the hand (Supplementary Note and Supplementary Table 11 ).
The strong phenotypic similarity refines the dosage-sensitive region to only three genes ( Fig. 3b) , including MAPT, which is disrupted by one of these atypical deletions.
Gene content analysis
Encouraged by the additional refinement provided by atypical deletion events, we performed a gene-based analysis on the complete intellectual disability and/or developmental delay dataset as well as on case subsets partitioned by additional phenotypic data. We identified 615 genes as significantly deleted in any phenotype (Benjamini-Hochberg corrected P < 0.05; Supplementary Table 12 ), the vast majority of which associated with known pathogenic loci or subtelomeric alterations. An Ingenuity Pathways Analysis (IPA) (see URLs) showed significant enrichment in expected functional categories (for example, cardiovascular disease and developmental, endocrine system and developmental disorders).
We then expanded our analysis to include candidate associations with nominal significance, as the above analysis is likely to be overly conservative because of the high level of dependence between neighboring genes. An IPA of genes with a nominal P < 0.02 identified the same functional categories as above, suggesting that a large proportion of the nominally significant genes are likely relevant to morbidity. In addition to identifying genes within known genomic disorders, this analysis identified genes outside of these intervals. For example, we observed an excess of smaller deletions of SCN1A specifically in cases with epilepsy (P = 0.019), consistent with the literature 27 . CD44 deletions on 11p13 were significantly enriched in craniofacial cases (P = 0.010) and have previously been linked to cleft lip and palate in SNP and expression A r t i c l e s microarray studies 28, 29 . A region on 9p24 containing five genes was significantly enriched in craniofacial cases, with the peak significance focused at SLC1A1 (peak P = 0.00172), which encodes a high affinity glutamate transporter previously implicated in multiple neurological conditions 30 . This peak, specific to SLC1A1, was also significantly enriched in neurological, craniofacial and epilepsy cases. A 2q37 deletion immediately proximal to the 2q37 deletion region ( Table 1) containing 15 genes was enriched primarily in the neurological (modal P = 0.00479) and epilepsy (modal P = 0.00542) phenotypes and contains genes associated with neurodevelopmental and sleep phase disturbances (GBX2 and PER2) 31, 32 . Finally, the deletion of PARD3 was significantly enriched in autism cases (P = 0.01023). PARD3 has been previously associated with bipolar disease 33 and is involved in both tight junction formation and axonal fate determination 34 . We also identified 325 duplicated genes ( Supplementary Table 12 ) significantly enriched among the cases (Benjamini-Hochberg corrected P < 0.05). Similar to deletions, nearly all genes enriched among duplications at this stringent threshold were within known pathogenic duplications and were overrepresented (according to IPA) in categories that fit well with the expected phenotypic abnormalities (for example, cardiovascular disease, developmental, endocrine system and developmental disorders). Expanding our analysis to enrichments with nominal significance identified IPA functions identical to the conservative approach as well as several promising candidate gene regions. We observed duplications containing three genes (SH3YL1, ACP1 and FAM150B) on chromosome 2p in cases with craniofacial disorders (P = 0.01032). Notably, large 2p distal duplications have been associated with facial dysmorphism in multiple case reports 35, 36 . Similarly, we observed duplication of two genes (RSPO4 and PSMF1) on distal chromosome 20p in cases with cardiac defects (P = 0.01195), and larger duplications of 20p have been associated with cardiac defects 37 . The results suggest a potential role for these small subtelomeric regions in disease. Finally, we observed duplication of proximal 8p extending to include two genes in cases with neurological disorders (P = 0.00479), one of which (FNTA) has been shown to be more highly expressed in schizophrenia 38 .
Discovery of smaller gene-disrupting CNVs
Although the data suggest that as much as 14.2% of developmental delay may be explained by large CNVs, many causal mutations remain to be identified. We sought to determine if previously unreported smaller CNVs could be identified among these cases, assuming that breakpoints would not necessarily be recurrent and that individually relevant events would be rare (<0.1%); such variants may, in principle, identify new candidate genes, refine the molecular basis for the phenotypic consequences of larger CNVs and broaden the predictive power of a given microarray experiment. Therefore, we conducted a directed search for small, exon-affecting CNVs, reasoning that such variants are more likely to have disease relevance and would be amenable to follow up. For each consensus coding sequence (CCDS) exon 39 , we determined the average intensity for the three closest probes (termed a 'cassette') in each sample and, in turn, identified cassettes with outlier intensities that may be indicative of deletions (Online Methods and Supplementary Fig. 6 ). Because this strategy is exon centric, it is partially platform and breakpoint independent. We analyzed 186,014 autosomal coding exons using 65,704 cassettes (multiple exons are often targeted by the same cassette) excluding exons within known common CNVs 16, 40, 41 . After a series of data normalization and quality-control steps, we identified 829 cassettes in which a small (10-100) set of samples had probe intensities that clustered well below the population-wide mean. Each of these cassettes was manually reviewed to eliminate artifacts and select for genes with greater potential for disease involvement; we selected 19 of these genes for follow up and organized them into two subjectively defined tiers of quality ( Table 3) .
Among the first tier of predicted deletions, we found that 55 of 58 individual (sample-level) predictions validated, with at least one validated event for all ten examined genes, and for the second tier, we found that 25 of 40 predictions validated across seven of the nine examined genes. A total of 44 of the validated deletions spanned only a single probe on the originally used array (Supplementary Fig. 7) . We determined deletion events at three genes to be polymorphisms [42] [43] [44] . Notably, we found PARK2 to contain at least six distinct exon-affecting deletions ranging in size from 118-315 kb ( Fig. 4, Supplementary  Fig. 8 and Supplementary Note) . However, there is no evidence for CNV enrichment at this locus among cases, as this phenomenon also holds true for control samples (Supplementary Fig. 9 ), suggesting that PARK2 is a fragile gene prone to recurrent deletion events. We also identified small deletions in TBX5, a gene known to cause Holt-Oram syndrome 45 (a disorder characterized by upper limb abnormalities and congenital heart defects; MIM#142900). We found that 7 of 15 samples predicted to harbor a TBX5 event were fetal samples, a rate significantly greater than the background proportion of fetal samples (13.4%, P = 0.0019), consistent with the observations that TBX5 mutations can result in prenatal abnormalities detectable by ultrasound 46 .
DISCUSSION
We present one of the largest studies investigating the role of rare CNVs in intellectual disability and developmental delay, analyzing data from 15,767 affected individuals and 8,329 controls. These data quantify the massive contribution of large CNVs to pediatric disease, with 25.7% of affected individuals harboring CNVs >400 kb compared with only 11.5% of controls. Disease risk increases steadily in relation to CNV size, with an OR > 20 for carriers of CNVs larger than 1.5 Mb and an OR of nearly 50 at a threshold of 3 Mb. We find that the CNV burden differs significantly depending on the nature of the primary clinical referral, with craniofacial abnormalities and structural defects of the heart being especially enriched for large CNVs relative to epilepsy and autism spectrum disorder ( Fig. 1 and  Supplementary Fig. 2) . As has been observed in model organisms and predicted based on theory 47, 48 , haploinsufficiency appears more common and penetrant than triplosensitivity for severe developmental phenotypes. Although this cohort does not represent a random sampling of individuals with intellectual disability and/or developmental delay and includes some individuals without these phenotypes, our estimates are likely applicable to intellectual disability and/or developmental delay in general. For example, in a literature survey 49 , the average CNV burden across 15 genome-wide studies of intellectual disability and/or developmental delay (with a combined sample size of 1,021) was estimated to be ~13.7%, which is similar to our estimate of 14.2% (note that this estimate was derived by averaging the diagnostic yields for all studies with a genome-wide resolution of 1 Mb or better as indicated in Table 2 of Miller et al. 49 ). Furthermore, the observed enrichment for many loci known to contribute to intellectual disability and/or developmental delay risk ( Table 1) and individual genes previously identified to be disrupted among affected individuals ( Supplementary Table 12 ) clearly supports the applicability of the inferences generated here for both intellectual disability and/or developmental delay specifically and for neurological disease (for example, schizophrenia and autism) in general.
Practically, these data serve as a clinical resource that will be useful in diagnostics (Tables 1 and 2) . The large number of controls and cases used here provides estimates of penetrance for 59 pathogenic CNVs (accounting for ~10% of cases) and sheds light on either ambiguous or previously unknown pathogenic variants, including 14 new or previously marginally supported CNV loci that collectively represent ~0.7% (112/15,767; Table 2 and Supplementary Note) of the individuals studied here. We note that although one CNV locus (10p15.3 duplications) appeared to be enriched among cases as a result of ancestry differences between the cases and controls, the aggregate ethnic composition of the 14 loci in Table 2 closely matched our control dataset (Supplementary Note and Supplementary Figs. 10 and 11) , suggesting that population stratification for rare variants is unlikely to explain the enrichment at these loci. The size distribution (median of 940 kb), inheritance rate (15 of 34 tested CNVs are de novo, with at least one de novo variant observed in 6 of the 14 loci) and overlap with DECIPHER entries further support a role for these CNV loci in disease risk.
Among these new potentially pathogenic CNVs, we provide additional support for a genomic disorder mapping to 15q25.2, which we found in five affected individuals (including two affected siblings) and zero controls (Supplementary Fig. 12 ). Our results, combined with earlier studies of schizophrenia and autism (four cases compared to zero controls) 16 , implicate this CNV as a high-risk allele for pediatric neurological disease with variable outcomes (Supplementary Note  and Supplementary Table 9 ) as well as neuropsychiatric disease (P = 0.037). In addition, our data support the pathogenicity of CNVs at 2q13 whose significance was uncertain because they were observed in a small number of control samples 50 . In our study, we observed 12 deletions (P = 0.032) and 9 duplications (P = 0.022) on chromosome 2q13 in cases but only 1 deletion in controls. We furthermore find an enrichment of the deletion in cardiovascular cases (peak P = 0.012) and the duplication in cases with craniofacial features (peak P = 0.010). These results are consistent with two previously reported deletion cases with multiple heart defects and two duplication cases with various facial and skeletal features 50 . Additionally, our data support the pathogenicity of duplications at 16p11.2 (SH2B1), duplications at 15q13.3 segmental duplication breakpoints BP3-BP5 (CHRNA7), and deletions at 15q11.2 involving segmental duplication breakpoints BP1-BP2 (NIPA1). The latter are present in ~1 in 167 affected individuals studied here and, although incompletely penetrant (12.8%), are likely strong risk factors for developmental delay in addition to schizophrenia 4,51 .
A r t i c l e s Finally, the discovery of atypical and smaller deletions among cases with virtually identical phenotypes helps to refine the smallest region of overlap for known syndromes. The atypical deletions of 17q21.31 exclude deletions of CRHR1 as playing a role in this syndrome (although deletions of long-range regulatory elements that change CRHR1 expression cannot be ruled out) and narrow the likely candidates to three genes, including MAPT, which was disrupted by proximal breakpoints in two cases (Fig. 3b) . Overall, we identified 615 deleted genes and 325 duplicated genes significantly enriched in cases when compared to controls. The dosage imbalance of these genes should not be considered as proven but, rather, these genes should be considered as candidates with higher prior probability of dosage sensitivity for future studies. It is encouraging that this set includes a number of previously hypothesized and new associations between genes and particular traits ( Supplementary Table 12 ). In addition, our data show that even older, low-resolution microarray data afford discovery opportunities for CNVs that have not previously been detectable. Indeed, we successfully identified and confirmed dozens of small deletion events, several of which have plausible disease roles (for example, TBX5 deletions in Holt-Oram syndrome), including many detected by only a single probe in the original microarray experiment. As the underlying raw data from diagnostic laboratories is released, prospectively, there will be great potential for finding additional exon-altering deletions. Further validation of these and other candidates will yield new insights into the specific phenotypes affected by the loss or gain of individual genes. Although most arrays cannot robustly capture the small deletions we identified, such as those adjacent to exons of FGF9 and LYST (associated with Chediak-Higashi syndrome), control screening using PCR or other targeted high-throughput assays may be used to follow up individually interesting candidates (Supplementary Note).
We predict that this map of CNVs and potentially dosage-sensitive genes will be invaluable for both clinical and research purposes in the future. For example, researchers in a previous study 52 used an exontargeted microarray to identify a number of individual gene disruptions in individuals with intellectual disability and/or developmental delay that were of plausible but uncertain pathogenicity given their rarity. We find support for a number of these genes, including two (CREBBP and SLC1A1) that are significantly enriched among individuals here with similar phenotypes to those previously described (Supplementary Note). As genomic discovery efforts (especially exome sequencing) expand, the results described here should prove increasingly important to clinicians and researchers faced with the challenges of linking rare disruptive mutations to pediatric diseases.
URLs. Database of Genomic Variants, http://projects.tcag.ca/ variation/; Ingenuity Pathway Analysis, http://www.ingenuity.com/; InCHIANTI, http://www.inchiantistudy.net/; UCSC LiftOver tool, http://genome.ucsc.edu/.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/.
Accession codes. All CNV calls have been submitted to dbVar under accession nstd54.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METhODS
Cases. Samples from individuals with intellectual disability and/or developmental delay and related phenotypes were submitted to Signature Genomic Laboratories, LLC, mostly from the United States and Canada, for clinical microarray-based CGH. A total of 15,767 samples were analyzed, and 16,526 rare autosomal CNV calls were detected ( Supplementary Table 1 ) and deposited into dbVar (dbVar study accession nstd54) 54 . Informed consent was obtained to publish clinical information and photographs and to further characterize the CNVs present in the individuals with detailed information presented in this paper using a protocol approved by the Signature Genomic Laboratories, LLC, institutional review board. Although not a random set of children with intellectual disability and/or developmental delay, the presentations in our set are representative of those observed in a clinical diagnostic setting. The majority of the individuals in our set have intellectual disability and/or developmental delay; however, clinical features such as craniofacial and skeletal features, growth retardation, cardiovascular and renal defects, hypotonia, speech and motor deficits, hearing impairment, epilepsy and behavioral problems were also documented. We identified 575 cases with cardiovascular defects, 1,776 cases with epilepsy and/or seizure disorder, 1,379 cases with autism spectrum disorder, 3,898 cases with craniofacial defects and 8,772 cases with general neurological defects; many individuals had multiple subclassifications (Supplementary Fig. 13 ).
Controls. Controls were not ascertained specifically for neurological disorders, but all controls were obtained from adult samples providing informed consent, so developmental disorders should be exceedingly rare in this group. Of individuals with known ethnicity, 81.2% are Caucasian (primarily European descent), 2% are African or African American and 16.5% are other or mixed ancestry. Because of the slight enrichment of African-American cases compared to our control samples, we modeled the potential impact of large CNV stratification and found no evidence for an overall enrichment of unique large CNVs in the African-ancestry cohort (Supplementary Fig. 10 ). DNA was obtained from cell lines and blood-derived samples generated for association studies of various phenotypes. The data sets are detailed in Supplementary Table 4 . Data were obtained from the following sources: HGDP 16, 55 ; NINDS (dbGaP accession number phs000089) 16, 56 , PARC/PARC2 57, 58 ; London (parents of asthmatic children) 15 ; FHCRC (pre-release data provided courtesy of A. Aragaki, C. Kooperberg and R. Jackson as part of an ongoing genome-wide association study to identify genetic components of hip fracture in the Women's Health Initiative); InCHIANTI (data provided by InCHIANTI study of aging; see URLs) 15, 59 ; and Wellcome Trust Case Control Consortium 2, National Blood Services Cohort (WTCCC2 NBS) 60 . Control CNV arrays were analyzed as described previously 16 . Briefly, a Hidden Markov Model (HMM) based on both allele frequencies and total intensity values (logR) was used to identify putative alterations, followed by manual inspection of large CNVs (>100 probes and >1 Mb) in conjunction with user guided merging of nearby (<1 Mb between for arrays with <1 million probes and <200 kb for arrays with >1 million probes) calls, which represent a single region broken up by the HMM, or gaps. All samples on arrays with densities <1 million probes were filtered by a maximal genome-wide logR standard deviation (s.d.) of 0.25, whereas the high-density 1.2 million probe WTCCC2 data was filtered using an increased s.d. cutoff of 0.37. Large alterations with non-canonical allele frequencies indicative of mosaics were excluded because of the high likelihood of these resulting from cell culture immortalization. For the two datasets where the Illumina array mapping corresponded to build35 (National Human Genome Research Institute), we used the autosomal calls generated previously 16 and mapped the coordinates to build36 using the UCSC LiftOver tool (see URLs).
Multi-platform CNV comparison. Microarray platform heterogeneity may yield false CNV enrichments signals as a function of differential detection power related to probe density, data quality, analysis methods, or other factors.
We made a number of efforts to control for such potential effects, and we believe our study design is robust to this source of error for a number of reasons. First, the control data for this study were generated on higher resolution platforms (317,000-1,200,000-probe Illumina SNP arrays, with 88% of controls being profiled on 550,000-probe or higher density platforms) compared to the case data (where the median array is ~97,000 probes and the highest density is ~130,000 probes). As a result, our CNV detection power is substantially higher for cases than controls; notably, such differences will tend to manifest as false positive enrichments for CNVs in controls whereas we are focused exclusively on enrichments within cases. Second, we rigorously eliminated potential sources of errors in the case CNV data with a combination of both manual and automated filters, including calls with low probe counts, high degrees of overlap with segmental duplications in the reference assembly and likely reference-sample CNVs. Third, for the sliding-window enrichment tests, we eliminated all CNVs in cases that spanned fewer than ten probes on the lowest resolution (HH317K) control SNP array. Fourth, we validated 402 of 425 CNVs and determined the precision in cases to be high in general (0.945) and higher in cases relative to controls (0.892). Fifth, we specifically analyzed the 14 potentially pathogenic CNVs ( Table 2 ) for control SNP microarray performance. Eleven of 14 loci harbored small CNV calls within the region of interest from multiple control studies; as CNV calling algorithms tend to show increased sensitivity to larger alterations, we consider this to indicate sufficient control sensitivity within these loci to detect large CNVs. The remaining three loci are split between the minimal common region on 1q24.3, which shows a single 72-kb CNV in controls (again suggesting detectability of larger events), and two loci that harbor very small CNVs detectable only on the highest resolution 1.2 million probe arrays. These two regions have high probe coverage on the 550,000 control array (46 probes within the smallest 6p22.3 Signature call and 40 probes in the minimal common region of 2q24.3). Further, all of these regions have de novo CNVs in our samples, supporting the hypothesis that these are pathogenic loci and not simply common CNVs that we failed to detect with SNP platforms.
Control CNV burden. Control CNVs were merged into copy number variant regions (CNVRs) by comparing each CNV to all of its overlapping partners and merging those with 50% reciprocal overlap. These CNVRs were then analyzed in the context of sliding 300-kb genomic windows to identify regions of high variability ( Supplementary Fig. 9 and Supplementary Table 13 ). Regions of high SNP diversity were obtained from a previous study 44 and used to identify regions where the breakpoint variability is likely to result from general sequence variation (such as the HLA locus on 6p). To perform a gene-based search for highly variable loci, we first generated a merged RefSeq list that combined overlapping splice variants into a single, large gene definition. We then analyzed these loci in the context of overlapping gain and loss CNVs that contained the entire gene, overlapped the transcript (gene-breaking or exon hits) or were contained within an intron. Finally, we analyzed each gene in the context of the number of unique CNVRs that overlapped the gene space (exonic or intronic).
Discovery of new exon-altering CNVs.
For a subset of 11,529 samples, we identified for each coding exon 39 the three closest probes, requiring at least one probe on both sides within 100 kb of the exon. We required that all probes map within 200 kb, yielding 65,704 unique cassettes targeting 186,014 autosomal coding exons. We then determined the average cassette intensity for each sample and normalized it by array type. Subsequently, we considered filtered cassettes by the following criteria: 10-100 samples with scores at least 5 s.d. below average; the subset of samples at less than 5 s.d. below average compose at least 10% of samples with scores less than 3 s.d. below average (a measure of cluster separation); and no overlap of the target exon (note that individual probes were not filtered given the heterogeneity of platforms and the potential for atypical CNVs) with common copy number polymorphisms or deletions seen in multiple control individuals 16, 42, 43, 61 . This yielded 829 candidates for follow up, each of which was manually reviewed to eliminate cassettes in which all candidate deletions clustered within a single array type suggestive of a batch artifact and noisy cassettes resulting from probes embedded within segmental duplications (for examples, see Supplementary Fig. 6 ). Subsequently, 19 cassettes were chosen for validation, manually divided into two qualitative tiers based on the totality of the evidence (for example, follow-up potential of the affected gene, visual analysis of probe intensity distributions, and so on).
